These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 29412119)

  • 1. Sodium-glucose Cotransporter 2 Inhibitors and Ischemic Stroke.
    Milonas D; Tziomalos K
    Cardiovasc Hematol Disord Drug Targets; 2018; 18(2):134-138. PubMed ID: 29412119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sodium-glucose Cotransporter 2 Inhibitors: Potential Cardiovascular and Mortality Benefits.
    Lovic D; Pittaras A; Kallistratos M; Tsioufis C; Grassos C; Djordjevic D; Tasic I; Manolis A
    Cardiovasc Hematol Disord Drug Targets; 2018; 18(2):114-119. PubMed ID: 29485012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential Therapeutic Effects of Sodium Glucose-linked Cotransporter 2 Inhibitors in Stroke.
    Al Hamed FA; Elewa H
    Clin Ther; 2020 Nov; 42(11):e242-e249. PubMed ID: 33008610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sodium-glucose Cotransporter 2 Inhibitors: The Pleiotropic Mechanisms of Actions.
    Pantelidis P; Kalliakmanis A; Mitas C; Sideris M; Grassos C; Pittaras A; Manolis A
    Cardiovasc Hematol Disord Drug Targets; 2018; 18(2):86-93. PubMed ID: 29412123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sodium-glucose Cotransporter 2 Inhibitors: Glucose Lowering Against other Hypoglycemic Agents.
    Avranas K; Imprialos K; Stavropoulos K; Lales G; Manafis A; Skalkou A; Kihm L
    Cardiovasc Hematol Disord Drug Targets; 2018; 18(2):94-103. PubMed ID: 29412124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal effects of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes and renal impairment.
    Weir MR
    Postgrad Med; 2019 Aug; 131(6):367-375. PubMed ID: 31132013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sodium-glucose Cotransporter 2 Inhibitors: The Impact on Development and Progression of Heart Failure.
    Papademetriou V; Geladari E
    Cardiovasc Hematol Disord Drug Targets; 2018; 18(2):127-133. PubMed ID: 29618313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors and the Treatment of Type 2 Diabetes.
    Kramer CK; Zinman B
    Annu Rev Med; 2019 Jan; 70():323-334. PubMed ID: 30256723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sodium-glucose Cotransporter 2 Inhibitors: Nephroprotective Impact on Diabetic Kidney Disease.
    Stavropoulos K; Imprialos KP; Stavropoulos N; Bouloukou S; Kerpiniotis G; Dimitriadis K; Tsioufis C; Doumas M
    Cardiovasc Hematol Disord Drug Targets; 2018; 18(2):120-126. PubMed ID: 29412122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unsweetening the Heart: Possible Pleiotropic Effects of SGLT2 Inhibitors on Cardio and Cerebrovascular Alterations in Resistant Hypertensive Subjects.
    Pioli MR; Ritter AMV; Modolo R
    Am J Hypertens; 2018 Feb; 31(3):274-280. PubMed ID: 29186300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sodium-glucose Cotransporter 2 Inhibitors: Impact on Body Weight and Blood Pressure Compared with other Antidiabetic Drugs.
    Imprialos KP; Stavropoulos K; Stavropoulos N; Patoulias D; Petidis K; Grassos C; Dimitriadis K; Tsioufis C
    Cardiovasc Hematol Disord Drug Targets; 2018; 18(2):104-113. PubMed ID: 29412121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sodium glucose cotransporter (SGLT)-2 inhibitors: Do we need them for glucose-lowering, for cardiorenal protection or both?
    Scholtes RA; van Baar MJB; Lytvyn Y; Bjornstad P; Nieuwdorp M; Cherney DZI; van Raalte DH
    Diabetes Obes Metab; 2019 Apr; 21 Suppl 2(Suppl 2):24-33. PubMed ID: 30843294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sodium-glucose cotransporter 2 inhibitors: an evidence-based practice approach to their use in the natural history of type 2 diabetes.
    Schwartz SS; Ahmed I
    Curr Med Res Opin; 2016 May; 32(5):907-19. PubMed ID: 26854518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SGLT-2 Inhibitors and Cardiovascular Risk in Diabetes Mellitus: A Comprehensive and Critical Review of the Literature.
    Imprialos K; Faselis C; Boutari C; Stavropoulos K; Athyros V; Karagiannis A; Doumas M
    Curr Pharm Des; 2017; 23(10):1510-1521. PubMed ID: 28120716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
    Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
    Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors in patients with type II diabetes mellitus: A meta-analysis of placebo-controlled randomized trials.
    Saad M; Mahmoud AN; Elgendy IY; Abuzaid A; Barakat AF; Elgendy AY; Al-Ani M; Mentias A; Nairooz R; Bavry AA; Mukherjee D
    Int J Cardiol; 2017 Feb; 228():352-358. PubMed ID: 27866027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From Kidney Protection to Stroke Prevention: The Potential Role of Sodium Glucose Cotransporter-2 Inhibitors.
    Hsieh CY; Sung SF
    Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sodium-glucose Cotransporter 2 Inhibitors and the Risk of Diabetic Ketoacidosis; from Pathophysiology to Clinical Practice.
    Patoulias D; Manafis A; Mitas C; Avranas K; Lales G; Zografou I; Sambanis C; Karagiannis A
    Cardiovasc Hematol Disord Drug Targets; 2018; 18(2):139-146. PubMed ID: 29412120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials.
    Inzucchi SE; Zinman B; Wanner C; Ferrari R; Fitchett D; Hantel S; Espadero RM; Woerle HJ; Broedl UC; Johansen OE
    Diab Vasc Dis Res; 2015 Mar; 12(2):90-100. PubMed ID: 25589482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Do the SGLT-2 Inhibitors Offer More than Hypoglycemic Activity?
    Flores E; Santos-Gallego CG; Diaz-Mejía N; Badimon JJ
    Cardiovasc Drugs Ther; 2018 Apr; 32(2):213-222. PubMed ID: 29679303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.